8-KOther Events

QUEST DIAGNOSTICS INC 8-K Report (Apr 22, 2003)

Filed April 22, 2003For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) filed an 8-K on April 22, 2003, primarily to disclose its financial results for the first quarter ended March 31, 2003. The report includes a press release that serves as the main source of information regarding the company's performance during the period. Investors should review this press release for detailed financial figures, operational updates, and any forward-looking statements or guidance provided by the company. The filing also confirms the effective date of the report and provides signatory information from the Vice President and Chief Financial Officer, Robert A. Hagemann. As this 8-K focuses on the announcement of quarterly results, it's crucial for investors to examine the attached press release for specific revenue, profitability, and other key performance indicators that would inform investment decisions.

Key Highlights

  • 1Quest Diagnostics (DGX) filed an 8-K on April 22, 2003.
  • 2The primary purpose of the filing was to announce the company's financial results for the quarter ended March 31, 2003.
  • 3Exhibit 99.1, a press release dated April 22, 2003, contains the detailed financial information.
  • 4The report is furnished under Regulation FD Disclosure (Item 9) and Results of Operations and Financial Condition (Item 12).
  • 5Robert A. Hagemann, Vice President and Chief Financial Officer, signed the report on behalf of the company.
  • 6Investors are directed to the attached press release for the specific quarterly financial performance and results.

Frequently Asked Questions

The main purpose of this 8-K filing by Quest Diagnostics Incorporated on April 22, 2003, is to announce and provide disclosure regarding the company's financial results for the quarter ended March 31, 2003, through an attached press release.

The detailed financial results for the quarter ended March 31, 2003, are contained within the press release attached as Exhibit 99.1 to this 8-K filing.

This report was signed by Robert A. Hagemann, Vice President and Chief Financial Officer of Quest Diagnostics Incorporated.

Investors should look for key financial metrics such as revenue, net income, earnings per share (EPS), gross margins, operating expenses, and any guidance or outlook provided by the company for future periods.